心力衰竭随机对照试验中女性作为第一作者的代表性不足及其相关特征
本综述检索2000年至2019年高影响因子期刊发表的心衰随机对照试验,评估作者性别分布的时间趋势及女性作为第一作者的相关试验特征。共纳入403项RCT,女性第一作者、资深作者和通讯作者占比分别为15.6%、12.9%和11.4%,且比例随时间无变化。多中心、北美或欧洲协调、药物干预及男性资深作者的试验中女性第一作者几率更低。
要点
- 心衰RCT中女性第一作者、资深作者、通讯作者占比分别为15.6%、12.9%、11.4%,时间趋势无改善。
- 多中心、北美/欧洲协调、药物干预、男性资深作者的RCT中女性第一作者几率更低。
- 需针对性改善女性在心衰试验中的领导机会。
核心结论
- 女性在心衰RCT作者中代表性不足,且随时间无改善。
- 多中心、北美或欧洲协调、药物干预或男性资深作者的RCT中女性第一作者几率更低。
研究设计与样本
- 检索MEDLINE、EMBASE、CINAHL,纳入2000年1月1日至2019年5月7日发表于影响因子≥10期刊的心衰RCT,共403项。
- 评估作者性别分布的时间趋势,并用多因素logistic回归分析女性第一作者的相关特征。
主要发现
- 女性第一作者占比15.6%(95%CI 12.2%-19.6%),资深作者12.9%(95%CI 9.8%-16.6%),通讯作者11.4%(95%CI 8.5%-14.9%)。
- 女性作者比例随时间无变化。
- 多中心RCT中女性第一作者OR 0.58(95%CI 0.18-0.96,p=0.037)。
- 北美协调RCT中OR 0.21(95%CI 0.08-0.70,p=0.011),欧洲协调OR 0.33(95%CI 0.09-0.91,p=0.039)。
- 药物干预RCT中OR 0.42(95%CI 0.16-0.97,p=0.043),男性资深作者OR 0.50(95%CI 0.21-0.93,p=0.043)。
临床怎么用
- 识别女性领导机会较少的心衰RCT类型,针对性提供培训、导师制与赞助。
- 在试验设计与协调环节关注性别平衡,促进女性作者参与。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical trials change practice in cardiology, and leading them requires research training, mentorship, sponsorship, and networking. Women report challenges in obtaining these opportunities. OBJECTIVES: The purpose of this review was to evaluate temporal trends in representation of women as authors in heart failure (HF) randomized controlled trials (RCTs) published in high-impact medical journals and explore RCT characteristics associated with women as lead authors. METHODS: We searched MEDLINE, EMBASE, and CINAHL for HF RCTs published in journals with an impact factor ≥10 between January 1, 2000, and May 7, 2019. We assessed temporal trends in the gender distribution of authors, and used multivariable logistic regression to determine characteristics associated with women as lead authors. RESULTS: We identified 10,596 unique articles, of which 403 RCTs met inclusion criteria. Women represented 15.6% (95% confidence interval [CI]: 12.2% to 19.6%), 12.9% (95% CI: 9.8% to 16.6%), and 11.4% (95% CI: 8.5% to 14.9%) of lead, senior, and corresponding authors, respectively. The proportion of women authors has not changed over time. Women had lower odds of lead authorship in RCTs that were multicenter (odds ratio [OR]: 0.58; 95% CI: 0.18 to 0.96; p = 0.037), were coordinated in North America (OR: 0.21; 95% CI: 0.08 to 0.70; p = 0.011) or Europe (OR: 0.33; 95% CI: 0.09 to 0.91; p = 0.039), tested drug interventions (OR: 0.42; 95% CI: 0.16 to 0.97; p = 0.043), or had men as the senior author (OR: 0.50; 95% CI: 0.21 to 0.93; p = 0.043). CONCLUSIONS: Women are under-represented as authors of HF RCTs, with no change in temporal trends. Women had lower odds of lead authorship in RCTs that were multicenter, were coordinated in North America or Europe, tested drug interventions, or had men as senior authors.
引用
- Whitelaw S, Thabane L, Mamas MA, et al. Characteristics of Heart Failure Trials Associated With Under-Representation of Women as Lead Authors. J Am Coll Cardiol. 2020. PMID: 33092727. doi:10.1016/j.jacc.2020.08.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。